Additionally, future studies investigating how FXR modulates SOCS3 and consequently impacts STAT3 signaling in CSCs could facilitate the development of more effective treatments aimed at disrupting the CSCs, ultimately improving patient outcomes across various cancer types. This evidence concerns the gene NR1H4 and cancer.